Cerus's pathogen inactivation technology is positioned to become the global standard of care for safe blood transfusions. Shares can triple over the next 12-18 months.
Concord, CA-based Cerus Corp. (CERS) develops and markets the INTERCEPT Blood System designed to enhance blood safety by inactivating blood-borne pathogens in donated blood components intended for transfusion. It holds worldwide rights for the INTERCEPT Blood System for all three blood components, namely platelets, plasma and Red Blood Cells (RBCs). It received the CE marks for platelets and plasma, in 2007 and 2006 respectively, and currently markets them in Europe, the Middle East and the Commonwealth of Independent States (CIS) via a direct sales force and distributors. Its pathogen inactivation technology is inherently...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: